

Harvey D White

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1298926/publications.pdf>

Version: 2024-02-01

461
papers

67,835
citations

2215

99
h-index

718

252
g-index

474
all docs

474
docs citations

474
times ranked

40971
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. <i>Diabetologia</i> , 2022, 65, 101-112.	6.3	5
2	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. <i>European Heart Journal</i> , 2022, 43, 148-149.	2.2	13
3	Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?. <i>European Heart Journal</i> , 2022, 43, 1008-1011.	2.2	3
4	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120010390.	3.9	4
5	Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e023667.	3.7	19
6	Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin. <i>European Cardiology Review</i> , 2022, 17, e03.	2.2	7
7	Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study. <i>Journal of the American Heart Association</i> , 2022, 11, e020745.	3.7	14
8	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011069.	3.9	0
9	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. <i>American Journal of Medicine</i> , 2022, , .	1.5	0
10	Common genetic variants do not predict recurrent events in coronary heart disease patients. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 96.	1.7	0
11	Type 1, Type 2 Myocardial Infarction and Non-Ischemic Myocardial Injury – Opinion from the Front Lines. <i>American Journal of Medicine</i> , 2022, 135, 935-938.	1.5	2
12	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 330-340.	11.4	19
13	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	2.2	23
14	Zooming in on the Enigmas of Type 2 Myocardial Infarction. <i>Circulation</i> , 2022, 145, 1201-1204.	1.6	1
15	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. <i>American Heart Journal</i> , 2022, 251, 1-12.	2.7	4
16	BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk. <i>Heart</i> , 2022, 108, 1250-1252.	2.9	1
17	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	1.8	7
18	B-type Natriuretic Peptide and Long-term Cardiovascular Mortality in Patients With Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4

#	ARTICLE	IF	CITATIONS
19	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81
20	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	1.8	33
21	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	5.2	42
22	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	8.4	70
23	Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?. <i>Journal of the American Heart Association</i> , 2021, 10, e019796.	3.7	6
24	High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial. <i>BMJ, The</i> , 2021, 372, n355.	6.0	11
25	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	2.7	7
26	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	2.2	63
27	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	8.6	19
28	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2021, 143, 1109-1122.	1.6	46
29	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021, 290, 392-403.	6.0	8
30	Myocardial Infarction and Evolocumab. <i>JAMA Cardiology</i> , 2021, 6, 1220-1221.	6.1	1
31	Waiting room computer tablets to improve health literacy and cardiovascular outcomes. <i>Heart</i> , 2021, 107, 1607-1608.	2.9	2
32	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021, 6, 1440.	6.1	43
33	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	2.8	58
34	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	3.1	11
35	Cardiac death should be the primary endpoint for revascularization trials and meta-analyses. <i>European Heart Journal</i> , 2021, 42, 4697-4698.	2.2	7
36	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	6.1	10

#	ARTICLE	IF	CITATIONS
37	In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 26-33.	1.0	0
38	Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24. <i>Heart Lung and Circulation</i> , 2020, 29, 824-834.	0.4	1
39	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	2.8	296
40	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	2.2	51
41	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	2.2	117
42	Clinically Important Improvements in Risk Assessment by Adding High-Sensitivity Troponin Level to Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1263.	6.1	3
43	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006582.	2.2	5
44	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020, 41, 4114-4123.	2.2	35
45	The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55). <i>The Lancet Regional Health - Western Pacific</i> , 2020, 5, 100056.	2.9	23
46	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	2.8	48
47	Meta-Analysis of Bleeding Scores Performance for Acute Coronary Syndrome. <i>Heart Lung and Circulation</i> , 2020, 29, 1749-1757.	0.4	5
48	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	27.0	1,508
49	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. <i>Circulation</i> , 2020, 141, 1608-1617.	1.6	104
50	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	2.8	50
51	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020, 222, 157-165.	2.7	21
52	Impact of guideline-recommended versus non-guideline-recommended β -blocker and Doppler echocardiographic parameters on 1-year mortality in Thai ischemic cardiomyopathy patients: A prospective multicenter registry. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 8.	1.7	1
53	Deconstructing the Paradox of Smoking and Improved Short-Term Cardiovascular Outcomes After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1755-1757.	2.8	4
54	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. <i>Scientific Reports</i> , 2020, 10, 6169.	3.3	14

#	ARTICLE	IF	CITATIONS
55	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	2.7	5
56	Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
57	Research in the Antipodes at Green Lane. <i>European Heart Journal</i> , 2020, 41, 4081-4084.	2.2	0
58	Utilisation and maintenance of high-intensity statins following acute coronary syndrome and coronary angiography: opportunities to improve care (ANZACS-QI 26). <i>New Zealand Medical Journal</i> , 2020, 133, 21-40.	0.5	3
59	Outcomes after ST-elevation myocardial infarction presentation to hospitals with or without a routine primary percutaneous coronary intervention service (ANZACS-QI 46). <i>New Zealand Medical Journal</i> , 2020, 133, 64-81.	0.5	2
60	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
61	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	2.8	154
62	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019, 42, 797-805.	1.8	4
63	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.4	207
64	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	2.2	17
65	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
66	P1226 Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
67	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.	6.8	14
68	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	2.8	49
69	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
70	Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. <i>Physiological Genomics</i> , 2019, 51, 506-515.	2.3	4
71	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	2.7	4
72	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet</i> , 2019, 393, 407-415.	13.7	512

#	ARTICLE	IF	CITATIONS
73	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	2.2	45
74	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	21.4	549
75	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	2.8	64
76	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
77	Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e010641.	3.7	29
78	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y ₁₂ Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007445.	3.9	0
79	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	6.1	100
80	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. <i>Nature Genetics</i> , 2019, 51, 452-469.	21.4	89
81	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019, 208, 65-73.	2.7	14
82	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019, 278, 217-222.	1.7	6
83	Sex And Prognostic Significance of Self-Reported Frailty in Non-“ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 430-437.	1.7	7
84	The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design. <i>American Heart Journal</i> , 2019, 208, 11-20.	2.7	49
85	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	2.8	131
86	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G372-G386.	3.4	5
87	Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective. <i>European Heart Journal</i> , 2019, 40, e4-e7.	2.2	3
88	All-Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit. <i>Heart Lung and Circulation</i> , 2019, 28, 245-256.	0.4	19
89	Acute reperfusion for ST-elevation myocardial infarction in New Zealand (2015-2017): patient and system delay (ANZACS-QI 29). <i>New Zealand Medical Journal</i> , 2019, 132, 41-59.	0.5	1
90	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	2.7	13

#	ARTICLE	IF	CITATIONS
91	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes. <i>Coronary Artery Disease</i> , 2018, 29, 469-476.	0.7	4
92	Discharge timing and outcomes after uncomplicated non- σ ST-segment elevation acute myocardial infarction. <i>American Heart Journal</i> , 2018, 201, 103-110.	2.7	3
93	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005635.	3.9	13
94	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease. <i>Circulation</i> , 2018, 138, 712-723.	1.6	93
95	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E348-E355.	1.7	5
96	How Can You Have a Myocardial Infarction Without Significant Coronary Artery Disease? Whither MINOCA. <i>Heart Lung and Circulation</i> , 2018, 27, 649-651.	0.4	1
97	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	6.1	65
98	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 158-165.	1.0	7
99	First and recurrent ischaemic heart disease events continue to decline in New Zealand, 2005-2015. <i>Heart</i> , 2018, 104, 51-57.	2.9	20
100	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018, 283, 83-92.	6.0	57
101	Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2018, 196, 28-35.	2.7	10
102	Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 250, 49-55.	1.7	5
103	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009609.	3.7	9
104	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004755.	2.2	51
105	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	27.0	2,211
106	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , 2018, 13, e0204352.	2.5	2
107	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018, 39, 4112-4121.	2.2	49
108	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2379-2388.	4.4	29

#	ARTICLE	IF	CITATIONS
109	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non- σ ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1322-1329.	1.6	2
110	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 37-43.	1.4	10
111	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous σ Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	2.9	25
112	Fourth Universal Definition of Myocardial Infarction (2018). <i>Journal of the American College of Cardiology</i> , 2018, 72, 2231-2264.	2.8	2,285
113	Fourth Universal Definition of Myocardial Infarction (2018). <i>Circulation</i> , 2018, 138, e618-e651.	1.6	1,858
114	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	27.0	205
115	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 270, 96-101.	1.7	10
116	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018, 50, 26-41.	21.4	286
117	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. <i>Open Heart</i> , 2018, 5, e000752.	2.3	1
118	Management of suspected acute coronary syndrome patients admitted to cardiology or non-cardiology services at Auckland City Hospital: implications for future national data collection. <i>New Zealand Medical Journal</i> , 2018, 131, 30-39.	0.5	0
119	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehv525.	2.2	164
120	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 155-163.	1.0	1
121	Cangrelor With and Without Glycoprotein σ IIb/IIIa Inhibitors in σ Patients σ Undergoing Percutaneous σ Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	2.8	47
122	Modest Improvement of Reperfusion Times Across Multiple ST-Segment σ Elevation Myocardial Infarction Networks With Rapid Care Process Implementation but no Effect on Mortality. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, e004769.	3.9	1
123	Relationship Between Peak Troponin Values and Long σ Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
124	Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome. <i>Atherosclerosis</i> , 2017, 261, 19-25.	0.8	25
125	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non σ ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 1214-1226.	3.2	9
126	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. <i>American Heart Journal</i> , 2017, 188, 147-155.	2.7	2

#	ARTICLE	IF	CITATIONS
127	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017, 103, 1168-1176.	2.9	34
128	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 194-203.	2.7	26
129	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. <i>American Heart Journal</i> , 2017, 188, 156-166.	2.7	10
130	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	27.0	510
131	State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 165-176.	3.2	35
132	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	3.2	97
133	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 ^Â P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	3.2	19
134	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	6
135	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Tj ETQq1 1 0.7843174 rgrBT /Overlock 10 Tj 50 222	3.7	12
136	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
137	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq1 1 0.784314 rgrBT /Overlock 10 Tj 50 222	3.7	12
138	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Tj ETQq0 0 0.784314 rgrBT /Overlock 10 Tj 50 222	3.7	12
139	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
140	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq0 0 0 rgrBT /Overlock 10 Tj 50 222	1.6	12
141	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	1.7	22
142	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	2.8	95
143	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	7
144	Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. <i>International Journal of Cardiology</i> , 2017, 248, 361-368.	1.7	17

#	ARTICLE	IF	CITATIONS
145	Persistent psychological distress and mortality in patients with stable coronary artery disease. <i>Heart</i> , 2017, 103, 1860-1866.	2.9	50
146	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , 2017, 12, e0182115.	2.5	16
147	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	2.2	45
148	Proposed new industry code on unhealthy food marketing to children and young people: will it make a difference?. <i>New Zealand Medical Journal</i> , 2017, 130, 94-101.	0.5	7
149	A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. <i>New Zealand Medical Journal</i> , 2017, 130, 17-28.	0.5	3
150	30-day mortality after percutaneous coronary intervention in New Zealand public hospitals (ANZACS-QI 18). <i>New Zealand Medical Journal</i> , 2017, 130, 54-63.	0.5	1
151	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016, 37, ehv611.	2.2	25
152	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 322-323.	2.8	14
153	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , 2016, 99, 8-21.	6.2	60
154	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , 2016, 102, 1221-1229.	2.9	3
155	Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2016, 178, 55-64.	2.7	3
156	Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease. <i>Circulation</i> , 2016, 133, 1851-1860.	1.6	48
157	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016, 133, 1560-1573.	1.6	17
158	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016, 178, 1-8.	2.7	15
159	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2135-2144.	2.8	66
160	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016, 37, 1993-2001.	2.2	101
161	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1169-1178.	2.8	133
162	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. <i>Circulation</i> , 2016, 134, 723-733.	1.6	31

#	ARTICLE	IF	CITATIONS
163	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the <sc>TRILOGY ACS</sc> Trial. <i>Clinical Cardiology</i> , 2016, 39, 329-337.	1.8	7
164	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ^{AP})-TIMI 50. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	13
165	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2016, 134, 1314-1324.	1.6	127
166	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1667-1676.	2.9	8
167	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	4
168	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	2.9	38
169	Ruling-In Myocardial Injury and Ruling-Out Myocardial Infarction With the European Society of Cardiology 1-Hour Algorithm. <i>Circulation</i> , 2016, 134, 1542-1545.	1.6	29
170	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	10
171	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016, 99, 40-55.	6.2	82
172	Lipoprotein-associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	44
173	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016, 99, 22-39.	6.2	50
174	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26
175	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 839-846.	1.8	39
176	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	2.7	11
177	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	2.8	15
178	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 73.	6.1	22
179	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	2.8	25
180	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016, 67, 936-947.	2.8	35

#	ARTICLE	IF	CITATIONS
181	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	2.2	329
182	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 443-454.	1.0	43
183	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 231-242.	1.0	110
184	The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9). <i>New Zealand Medical Journal</i> , 2016, 129, 23-36.	0.5	8
185	High-sensitivity Cardiac Troponin T in Stable Patients Undergoing Pharmacological Stress Testing. <i>Clinical Cardiology</i> , 2015, 38, 293-299.	1.8	9
186	Efficacy and Safety of Vorapaxar in Non-ST-segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	8
187	Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002314.	3.9	22
188	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. <i>Heart</i> , 2015, 101, 279-286.	2.9	14
189	Post-operative aspartate aminotransferase levels independently predict mortality after isolated coronary artery bypass grafting. <i>IJC Metabolic & Endocrine</i> , 2015, 6, 31-35.	0.5	2
190	Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 428-433.	1.6	22
191	Resolution of ST depression after fibrinolysis can be more important than resolution of ST elevation for many patients with inferior STEMIs. <i>International Journal of Cardiology</i> , 2015, 182, 232-234.	1.7	8
192	Reply to letter by Kirat and Kóse: Maximizing information from a 12-lead electrocardiogram. <i>International Journal of Cardiology</i> , 2015, 197, 145-146.	1.7	1
193	Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 695-705.e5.	2.7	18
194	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the Tj ETQq0 0 0.6gBT /Overlock 10 T		
195	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 424-433.	2.9	35
196	ST deviations and serial changes after reperfusion therapy in patients with inferior STEMIs: Relationship between inferior leads, medial chest leads and lateral leads. <i>International Journal of Cardiology</i> , 2015, 184, 348-349.	1.7	6
197	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 357-367.	2.2	30
198	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 683-694.e3.	2.7	26

#	ARTICLE	IF	CITATIONS
199	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015, 201, 499-507.	1.7	42
200	Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1121-1129.	5.3	51
201	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
202	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 771-778.	1.8	41
203	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. <i>American Heart Journal</i> , 2014, 168, 682-689.e1.	2.7	365
204	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	7.4	375
205	A randomized trial evaluating the effects of change in dairy food consumption on cardio-metabolic risk factors. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1376-1386.	1.8	35
206	Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 516-523.	1.7	4
207	Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.7	9
208	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 619-629.	2.8	92
209	Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 174, 90-95.	1.7	2
210	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2884-2885.	2.8	0
211	Prognostic performance of kinetic changes of high-sensitivity troponin T in acute coronary syndrome and in patients with increased troponin without acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 174, 524-529.	1.7	9
212	Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina. <i>Journal of the American College of Cardiology</i> , 2014, 63, 345-354.	2.8	61
213	Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 266-275.	2.9	2
214	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. <i>JACC: Heart Failure</i> , 2014, 2, 159-165.	4.1	91
215	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	27.0	467
216	Diagnostic and Therapeutic Implications of Type 2 Myocardial Infarction: Review and Commentary. <i>American Journal of Medicine</i> , 2014, 127, 105-108.	1.5	103

#	ARTICLE	IF	CITATIONS
217	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014, 168, 76-87.e1.	2.7	22
218	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014, 35, 2516-2523.	2.2	83
219	Clinical implications of the Third Universal Definition of Myocardial Infarction. <i>Heart</i> , 2014, 100, 424-432.	2.9	46
220	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	2.8	212
221	Republished: Clinical implications of the Third Universal Definition of Myocardial Infarction. <i>Postgraduate Medical Journal</i> , 2014, 90, 502-510.	1.8	4
222	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage and Optimization (ACTO) Study). <i>Circulation</i> , 2014, 129, 1000-1007.	1.0	16
223	Importance of frailty in patients with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 1726-1731.	2.2	239
224	Prognosis of Patients With Non-ST-Segment Elevation Myocardial Infarction and Nonobstructive Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 285-293.	3.9	151
225	Torrent of Troponin. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 435-438.	3.9	2
226	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). <i>American Heart Journal</i> , 2014, 168, 588-596.	2.7	44
227	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 246-256.	1.0	13
228	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 335-343.	4.1	43
229	Universal MI Definition Update for Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2014, 16, 492.	2.9	32
230	Comparison of Four Risk Scores for Contemporary Isolated Coronary Artery Bypass Grafting. <i>Heart Lung and Circulation</i> , 2014, 23, 469-474.	0.4	20
231	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1048-1057.	2.8	40
232	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 113, 936-944.	1.6	17
233	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. <i>Lancet</i> , 2013, 382, 1981-1992.	13.7	286
234	The HERO-2 ECG sub-studies in patients with ST elevation myocardial infarction: Implications for clinical practice. <i>International Journal of Cardiology</i> , 2013, 170, 17-23.	1.7	13

#	ARTICLE	IF	CITATIONS
235	Rivaroxaban for the treatment of acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2013, 14, 917-927.	1.8	1
236	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. European Journal of Preventive Cardiology, 2013, 20, 678-685.	1.8	60
237	Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. Journal of the American College of Cardiology, 2013, 62, 242-251.	2.8	39
238	Avatar of the Universal Definition of Periprocedural Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 1571-1574.	2.8	23
239	Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. International Journal of Cardiology, 2013, 167, 1134-1140.	1.7	51
240	Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. Revista Española De Cardiología, 2013, 66, 132.e1-132.e15.	1.2	18
241	Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome. JACC: Heart Failure, 2013, 1, 223-229.	4.1	48
242	A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart, 2013, 99, 1282-1287.	2.9	28
243	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	27.0	695
244	Physical activity in patients with stable coronary heart disease: an international perspective. European Heart Journal, 2013, 34, 3286-3293.	2.2	67
245	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes. Coronary Artery Disease, 2013, 24, 321-327.	0.7	3
246	Diagnosis of MI after CABG with high-sensitivity troponin T and new ECG or echocardiogram changes: relationship with mortality and validation of the Universal Definition of MI. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 323-333.	1.0	44
247	Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. CKJ: Clinical Kidney Journal, 2013, 6, 402-409.	2.9	20
248	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. Circulation, 2013, 128, 823-833.	1.6	130
249	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA[CER]) trial. European Heart Journal, 2013, 34, 1723-1731.	2.2	36
250	Changes in Lipoprotein-Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long-term Intervention with Pravastatin in Ischemic Disease Study. Journal of the American Heart Association, 2013, 2, e000360.	3.7	47
251	Third universal definition of myocardial infarction. Srce I Krvni Sudovi, 2013, 32, 29-46.	0.1	0
252	Maori have worse outcomes after coronary artery bypass grafting than Europeans in New Zealand. New Zealand Medical Journal, 2013, 126, 12-22.	0.5	1

#	ARTICLE	IF	CITATIONS
253	Response to NZMJ editorial by Dr Elana Curtis entitled Deserving of more: framing of Māori inequities in cardiovascular care remain a challenge. <i>New Zealand Medical Journal</i> , 2013, 126, 132-3.	0.5	0
254	Lack of relationship between obesity and mortality or morbidity after coronary artery bypass grafting. <i>New Zealand Medical Journal</i> , 2013, 126, 56-65.	0.5	11
255	Higher mortality in women undergoing coronary artery bypass grafting. <i>New Zealand Medical Journal</i> , 2013, 126, 25-31.	0.5	16
256	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
257	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	27.0	765
258	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
259	New ST-depression: an under-recognized high-risk category of "complete" ST-resolution after reperfusion therapy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 210-221.	1.0	6
260	Patients with circumflex occlusions miss out on reperfusion. <i>Current Opinion in Cardiology</i> , 2012, 27, 327-330.	1.8	14
261	The Prequel. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 142-145.	3.9	22
262	The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 384-392.	2.2	44
263	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	27.0	701
264	Third universal definition of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012, 9, 620-633.	13.7	2,615
265	Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 182-190.e4.	2.7	89
266	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. <i>American Heart Journal</i> , 2012, 163, 563-571.	2.7	36
267	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012, 163, 768-776.e2.	2.7	72
268	Third Universal Definition of Myocardial Infarction. <i>Global Heart</i> , 2012, 7, 275.	2.3	309
269	We should cap the health budget and spend more money on housing and food: NO. <i>Journal of Primary Health Care</i> , 2012, 4, 339-41.	0.6	0
270	Pathobiology of Troponin Elevations. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2406-2408.	2.8	320

#	ARTICLE	IF	CITATIONS
271	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2309-2316.	2.8	49
272	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	27.0	918
273	Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. <i>American Heart Journal</i> , 2011, 161, 450-461.	2.7	30
274	Study design and rationale for the Stabilization of pLaques using Darapladibâ€”Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011, 162, 613-619.e1.	2.7	77
275	2011 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand guidelines for the management of acute coronary syndromes (ACS) 2006. <i>Heart Lung and Circulation</i> , 2011, 20, 487-502.	0.4	103
276	Antithrombotic therapy in ST-segment elevation myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 213-223.	1.8	2
277	The Role of Lipoprotein-Associated Phospholipase A2 as a Marker and Potential Therapeutic Target in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2011, 13, 132-137.	4.8	22
278	Effects of Dietary Factors on Lipoprotein-Associated Phospholipase A2 (Lp-PLA2). <i>Current Atherosclerosis Reports</i> , 2011, 13, 461-466.	4.8	4
279	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 654-664.	2.9	329
280	Prognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 769-777.	2.9	31
281	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
282	Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction. <i>Circulation</i> , 2011, 124, 2320-2328.	1.6	34
283	Management of ST-elevation myocardial infarction. , 2011, , 474-484.		0
284	Darapladib and its potential for plaque stabilization and prevention of cardiac events. <i>Clinical Lipidology</i> , 2010, 5, 465-476.	0.4	2
285	Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTEMI ACS: A subgroup analysis from the SYNERGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 928-935.	1.7	15
286	Response to Letter Regarding Article, â€œPrognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trialâ€• <i>Circulation</i> , 2010, 122, .	1.6	2
287	A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. <i>Personalized Medicine</i> , 2010, 7, 319-325.	1.5	5
288	Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial. <i>Circulation</i> , 2010, 121, 2724-2730.	1.6	74

#	ARTICLE	IF	CITATIONS
289	Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage. <i>Circulation</i> , 2010, 121, 853-862.	1.6	34
290	Prognostic Value of Lead V 1 ST Elevation During Acute Inferior Myocardial Infarction. <i>Circulation</i> , 2010, 122, 463-469.	1.6	30
291	aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 1845-1853.	2.2	65
292	Longitudinal study of a 9p21.3 SNP using a national electronic healthcare database. <i>Personalized Medicine</i> , 2010, 7, 361-369.	1.5	1
293	Rheumatic Heart Disease in Indigenous Populations. <i>Heart Lung and Circulation</i> , 2010, 19, 273-281.	0.4	51
294	Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. <i>International Journal of Cardiology</i> , 2010, 139, 123-133.	1.7	44
295	Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. <i>American Heart Journal</i> , 2010, 159, 110-116.	2.7	31
296	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY) Tj ETQq0 0 0 rgBT /Overflock 10 Tf	2.7	120
297	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf patients with coronary heart disease. <i>American Heart Journal</i> , 2010, 160, 655-661.e2.	2.7	111
298	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	18.7	725
299	The ATOLL trial of enoxaparin in primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 2826-7.	2.2	1
300	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	27.0	560
301	Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 529-538.	3.3	10
302	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2318-2329.	27.0	533
303	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009, 30, 1457-1466.	2.2	315
304	Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38. <i>Circulation</i> , 2009, 119, 2758-2764.	1.6	155
305	Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial?. <i>European Heart Journal</i> , 2009, 30, 2556-2557.	2.2	0
306	Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1083-1091.	2.9	38

#	ARTICLE	IF	CITATIONS
307	HORIZONS trial: a step forward for primary percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2009, 7, 125-129.	1.5	1
308	The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: Results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. American Heart Journal, 2009, 157, 125-131.	2.7	12
309	Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 53, 1021-1030.	2.8	125
310	Prognostic Significance of Periprocedural Versus Spontaneously Occurring Myocardial Infarction After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 477-486.	2.8	178
311	Strategies to minimize bleeding complications of percutaneous coronary intervention. Current Opinion in Cardiology, 2009, 24, 273-278.	1.8	9
312	Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. , 2009, , 293-340.		2
313	Fibrinolysis for Acute Myocardial Infarction. Fundamental and Clinical Cardiology, 2009, , 651-666.	0.0	0
314	Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial. Journal of General Internal Medicine, 2008, 23, 310-316.	2.6	44
315	Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy. Journal of the American College of Cardiology, 2008, 51, 1734-1741.	2.8	74
316	Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 52, 807-814.	2.8	72
317	Heart disease in Soweto: facing a triple threat. Lancet, The, 2008, 371, 876-877.	13.7	3
318	Acute myocardial infarction. Lancet, The, 2008, 372, 570-584.	13.7	557
319	Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial. Heart, 2008, 95, 276-282.	2.9	41
320	Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. European Heart Journal, 2008, 29, 1827-1833.	2.2	36
321	Systems of Care. Circulation, 2008, 118, 219-222.	1.6	30
322	Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. European Heart Journal, 2008, 29, 462-471.	2.2	63
323	Evolution of the definition of myocardial infarction: what are the implications of a new universal definition?. Heart, 2008, 94, 679-684.	2.9	25
324	Will new higher-precision troponins lead to clarity or confusion?. Current Opinion in Cardiology, 2008, 23, 292-295.	1.8	16

#	ARTICLE	IF	CITATIONS
325	Enoxaparin: a perspective on its use for coronary artery disease. <i>Aging Health</i> , 2008, 4, 579-591.	0.3	2
326	Diagnostic application of the universal definition of myocardial infarction in the intensive care unit. <i>Current Opinion in Critical Care</i> , 2008, 14, 543-548.	3.2	38
327	Glycoprotein IIb/IIIa Inhibitors. , 2008, , 65-86.		2
328	ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 851-857.	1.5	5
329	Elderly patients should not be denied fibrinolytic therapy. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 520-521.	3.3	0
330	Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 591.	7.4	266
331	Cardiovascular disease on a global scale: defining the path forward for research and practice. <i>European Heart Journal</i> , 2007, 28, 2678-2684.	2.2	28
332	Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. <i>European Heart Journal</i> , 2007, 28, 1066-1071.	2.2	89
333	Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2497.	7.4	217
334	Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. <i>European Heart Journal</i> , 2007, 28, 2525-2538.	2.2	1,856
335	Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control. <i>Archives of Internal Medicine</i> , 2007, 167, 239.	3.8	527
336	Acute Coronary Care in the Elderly, Part I. <i>Circulation</i> , 2007, 115, 2549-2569.	1.6	693
337	Acute Coronary Care in the Elderly, Part II. <i>Circulation</i> , 2007, 115, 2570-2589.	1.6	489
338	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
339	Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: Insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. <i>American Heart Journal</i> , 2007, 154, 313-321.	2.7	16
340	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>Lancet, The</i> , 2007, 369, 907-919.	13.7	367
341	Direct Antithrombins. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 249-257.	2.2	14
342	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. <i>Heart Rhythm</i> , 2007, 4, 308-313.	0.7	21

#	ARTICLE	IF	CITATIONS
343	Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1362-1368.	2.8	776
344	Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2173-2195.	2.8	1,557
345	Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 73-83.	1.7	106
346	Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. <i>Vascular Health and Risk Management</i> , 2007, 3, 425-30.	2.3	18
347	Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. <i>European Heart Journal</i> , 2006, 27, 21-28.	2.2	104
348	Risk Stratification of Patients With Acute Anterior Myocardial Infarction and Right Bundle-Branch Block. <i>Circulation</i> , 2006, 114, 783-789.	1.6	61
349	Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. <i>Lancet</i> , The, 2006, 367, 2061-2067.	13.7	68
350	A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1346-1354.	2.8	79
351	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 355, 2395-2407.	27.0	635
352	Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. <i>American Heart Journal</i> , 2006, 152, 1042-1050.	2.7	85
353	Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2006, 355, 1006-1017.	27.0	325
354	Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 354, 1477-1488.	27.0	556
355	Bivalirudin for Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 355, 2203-2216.	27.0	1,367
356	Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2511.	7.4	572
357	Facilitated percutaneous coronary intervention: Is this strategy ready for implementation?. <i>Current Cardiology Reports</i> , 2005, 7, 235-241.	2.9	2
358	White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. <i>Circulation</i> , 2005, 111, 1756-1762.	1.6	59
359	Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction. <i>Circulation</i> , 2005, 112, 3391-3399.	1.6	101
360	High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2594.	7.4	57

#	ARTICLE	IF	CITATIONS
361	Adherence and outcomes: it's more than taking the pills. <i>Lancet</i> , The, 2005, 366, 1989-1991.	13.7	36
362	Comparison of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting After Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>Circulation</i> , 2005, 112, 1992-2001.	1.6	210
363	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2005, 149, 217-226.	2.7	83
364	Design and methodology of the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2005, 150, 627-642.	2.7	56
365	Functional Status and Quality of Life After Emergency Revascularization for Cardiogenic Shock Complicating Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 266-273.	2.8	113
366	Patients With Prolonged Ischemic Chest Pain and Presumed-New Left Bundle Branch Block Have Heterogeneous Outcomes Depending on the Presence of ST-Segment Changes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 29-38.	2.8	74
367	Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 979.	7.4	393
368	Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials.. <i>Blood</i> , 2005, 106, 902-902.	1.4	1
369	PHARMAC and lack of funding for clopidogrel. <i>New Zealand Medical Journal</i> , 2005, 119, U1808.	0.5	1
370	We Must Use the Knowledge That We Have to Treat Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 698-700.	1.6	9
371	Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1307.	7.4	1,166
372	Clinical implications of the new definition of myocardial infarction. <i>British Heart Journal</i> , 2004, 90, 99-106.	2.1	128
373	Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 45-54.	7.4	702
374	Acute myocardial infarction: Fibrinolytic therapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 15-28.	0.9	3
375	Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2004, 351, 1285-1295.	27.0	1,712
376	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. <i>American Heart Journal</i> , 2004, 148, 764-775.	2.7	231
377	Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: Results from the SHOCK trial. <i>American Heart Journal</i> , 2004, 148, 810-817.	2.7	15
378	Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. <i>Annals of Thoracic Surgery</i> , 2004, 77, 925-931.	1.3	121

#	ARTICLE	IF	CITATIONS
379	Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2004, 292, 55.	7.4	218
380	Missed opportunities for better health outcomes in New Zealand. New Zealand Medical Journal, 2004, 117, U1002.	0.5	0
381	Significance of Atrial Fibrillation During Acute Myocardial Infarction, and its Current Management: Insights from the GUSTO-3 Trial. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 201-207.	1.0	50
382	Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. Journal of the American College of Cardiology, 2003, 42, 1380-1386.	2.8	274
383	Candesartan and heart failure: the allure of CHARM. Lancet, The, 2003, 362, 754-755.	13.7	38
384	Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?. Lancet, The, 2003, 362, 755-757.	13.7	35
385	Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase. American Heart Journal, 2003, 145, 95-102.	2.7	30
386	International variation in the use of evidence-based medicines for acute coronary syndromes. European Heart Journal, 2003, 24, 2133-2141.	2.2	35
387	Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. European Heart Journal, 2003, 24, 172-181.	2.2	39
388	Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. European Heart Journal, 2002, 23, 399-404.	2.2	24
389	Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension, 2002, 20, 2513-2517.	0.5	8
390	Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2002, 288, 2130.	7.4	125
391	Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. Expert Opinion on Pharmacotherapy, 2002, 3, 777-788.	1.8	15
392	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, The, 2002, 359, 189-198.	13.7	944
393	Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: A substudy of the GUSTO-III trial. American Heart Journal, 2002, 144, 81-88.	2.7	63
394	Things ain't what they used to be: Impact of a new definition of myocardial infarction. American Heart Journal, 2002, 144, 933-937.	2.7	26
395	Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction. American Journal of Cardiology, 2002, 90, 54-57.	1.6	17
396	Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender*. Clinical Pharmacology and Therapeutics, 2002, 71, 433-439.	4.7	171

#	ARTICLE	IF	CITATIONS
397	Long-term risk stratification for survivors of acute coronary syndromes. Journal of the American College of Cardiology, 2001, 38, 56-63.	2.8	112
398	Management of unstable angina. Guidelines " 2000. Medical Journal of Australia, 2001, 174, 423-424.	1.7	2
399	Relation of pathologic Q waves at presentation and time to streptokinase therapy with early changes in infarct-related artery flow and ventricular wall motion. American Journal of Cardiology, 2001, 88, 558-561.	1.6	8
400	One-Year Survival Following Early Revascularization for Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2001, 285, 190.	7.4	575
401	Door-to-needle times: Room for improvement and need for continuous audit. EMA - Emergency Medicine Australasia, 2000, 12, 91-94.	1.1	0
402	Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?. , 2000, 1, 150.		6
403	Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 245-253.	2.3	171
404	The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolized: methods and design. Journal of Thrombosis and Thrombolysis, 2000, 10, 241-246.	2.1	24
405	Thrombolytic therapy in the elderly. Lancet, The, 2000, 356, 2028-2030.	13.7	154
406	Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?. Journal of Invasive Cardiology, 2000, 12 Suppl A, 6A-13A.	0.4	0
407	Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock. New England Journal of Medicine, 1999, 341, 625-634.	27.0	2,596
408	Antithrombin agents as adjuncts to thrombolytic therapy. , 1999, 8, 159-166.		2
409	Direct thrombin inhibitors as adjuncts to thrombolytic therapy. Current Cardiology Reports, 1999, 1, 184-191.	2.9	2
410	Usefulness of the presenting electrocardiogram in predicting successful reperfusion with Streptokinase in acute myocardial infarction. American Journal of Cardiology, 1999, 83, 164-168.	1.6	43
411	Stent deformation following simulated side-branch dilatation: A comparison of five stent designs. Catheterization and Cardiovascular Interventions, 1999, 47, 258-264.	1.7	116
412	Future of reperfusion therapy for acute myocardial infarction. Lancet, The, 1999, 354, 695-697.	13.7	23
413	Long-Term Survival and Valve-Related Complications in Young Women With Cardiac Valve Replacements. Circulation, 1999, 99, 2669-2676.	1.6	157
414	Is thrombin a pharmacological target during reperfusion?. Blood Coagulation and Fibrinolysis, 1999, 10 Suppl 1, S55-7.	1.0	0

#	ARTICLE	IF	CITATIONS
415	Thrombolytic eligibility. Australian and New Zealand Journal of Medicine, 1998, 28, 518-524.	0.5	1
416	Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO 2) Study. Australian and New Zealand Journal of Medicine, 1998, 28, 551-554.	0.5	13
417	Low molecular weight heparins in acute ischaemic syndromes. Australian and New Zealand Journal of Medicine, 1998, 28, 555-557.	0.5	1
418	New antiplatelet agents. Australian and New Zealand Journal of Medicine, 1998, 28, 558-564.	0.5	4
419	The corrected TIMI frame count. The new gold standard?. Australian and New Zealand Journal of Medicine, 1998, 28, 569-573.	0.5	10
420	Thrombolysis for Acute Myocardial Infarction. Circulation, 1998, 97, 1632-1646.	1.6	192
421	Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes. Expert Opinion on Investigational Drugs, 1998, 7, 811-821.	4.1	2
422	Applying the open artery theory: use of predictive survival markers. European Heart Journal, 1998, 19, 1132-1139.	2.2	46
423	Should all occluded infarct-related arteries be opened?. European Heart Journal, 1997, 18, 1207-1209.	2.2	23
424	Selection of thrombolytic therapy for individual patients: Development of a clinical model. American Heart Journal, 1997, 133, 630-639.	2.7	77
425	Is heparin of value in the management of acute myocardial infarction?. , 1997, 11, 111-119.		8
426	Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis. , 1997, 4, 317-319.		4
427	Coronary Artery Patency and Survival in Clinical Trials. Journal of Thrombosis and Thrombolysis, 1997, 4, 239-250.	2.1	1
428	Clinical Trials of Direct Thrombin Inhibitors in Acute Ischaemic Syndromes. Thrombosis and Haemostasis, 1997, 78, 364-366.	3.4	15
429	Comparison of case fatality in smokers and non-smokers after acute cardiac event. BMJ: British Medical Journal, 1997, 315, 992-993.	2.3	24
430	Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO). Circulation, 1997, 96, 2155-2161.	1.6	207
431	Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. Thrombosis and Haemostasis, 1997, 78, 364-6.	3.4	3
432	Thrombolytic Therapy in the Elderly. Drugs and Aging, 1996, 8, 237-244.	2.7	11

#	ARTICLE	IF	CITATIONS
433	Effects of Thrombolytic Therapy on Left Ventricular Function and the Importance of Long-Term Patency of the Infarct-Related Artery. <i>Clinical Science</i> , 1995, 88, 21-24.	4.3	3
434	LEFT VENTRICULAR FUNCTION FOLLOWING THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, 173-179.	1.9	4
435	Lifting the smoke-screen: The enigma of better outcome in smokers after myocardial infarction. <i>American Journal of Cardiology</i> , 1995, 75, 278-279.	1.6	12
436	Effects of streptokinase in patients presenting within 6 hours of prolonged chest pain with ST segment depression.. <i>Heart</i> , 1995, 73, 500-505.	2.9	15
437	Evaluation of paradoxical beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. <i>Journal of the American College of Cardiology</i> , 1995, 26, 1222-1229.	2.8	209
438	Angioplasty versus bypass surgery. <i>Lancet</i> , The, 1995, 346, 1174-1175.	13.7	18
439	Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion. <i>Circulation</i> , 1995, 91, 1923-1928.	1.6	416
440	Thrombolytic therapy for acute myocardial infarction: where are we now? Where should we go?. <i>Chinese Medical Journal</i> , 1995, 108, 462-5.	2.3	0
441	Selecting a thrombolytic agent. <i>Cardiology Clinics</i> , 1995, 13, 347-54.	2.2	3
442	Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction.. <i>Circulation</i> , 1994, 89, 61-67.	1.6	212
443	Aspirin or warfarin for non-rheumatic atrial fibrillation?. <i>Lancet</i> , The, 1994, 343, 683-684.	13.7	15
444	Allergic Reactions to Streptokinase. <i>BioDrugs</i> , 1994, 2, 415-420.	0.7	8
445	FACTORS AFFECTING OUTCOME AFTER RECOVERY FROM MYOCARDIAL INFARCTION. <i>Annual Review of Medicine</i> , 1994, 45, 325-339.	12.2	21
446	Comparative Tolerability Profiles of Thrombolytic Agents. <i>Drug Safety</i> , 1993, 8, 19-29.	3.2	13
447	Issues raised by GUSTO. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 739-741.	0.5	1
448	Hirudin and Hirulog. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 769-770.	0.5	2
449	Pharmacoeconomic Aspects of Treatment of Acute Myocardial Infarction with Thrombolytic Agents. <i>Pharmacoeconomics</i> , 1993, 3, 192-204.	3.3	8
450	After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.. <i>Circulation</i> , 1993, 88, 2097-2103.	1.6	157

#	ARTICLE	IF	CITATIONS
451	Reperfusion injury - a reply to Keith Fox. Cardiovascular Research, 1992, 26, 660-661.	3.8	3
452	Remodelling of the heart after myocardial infarction. Australian and New Zealand Journal of Medicine, 1992, 22, 601-606.	0.5	6
453	Thrombolytic therapy for patients with myocardial infarction presenting after six hours. Lancet, The, 1992, 340, 221-222.	13.7	26
454	Heart failure: to digitalise or not? The view against. Australian and New Zealand Journal of Medicine, 1992, 22, 626-630.	0.5	2
455	Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.. Heart, 1990, 64, 177-181.	2.9	60
456	GISSI-2 and the heparin controversy. Lancet, The, 1990, 336, 297-298.	13.7	51
457	The management of myocardial infarction: an update. Comprehensive Therapy, 1990, 16, 11-5.	0.2	0
458	Acute myocardial infarction: a true medical emergency. New Zealand Medical Journal, 1989, 102, 281-3.	0.5	1
459	Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial Infarction. New England Journal of Medicine, 1987, 317, 850-855.	27.0	646
460	Liver disease induced by perhexiline maleate. Medical Journal of Australia, 1982, 2, 9-10.	1.7	8
461	Coronary Artery Bypass Grafting. , 0, , 240-255.		0